Comparative Effectiveness of Proton Pump Inhibitors vs Histamine Type 2 Receptor Blockers for Preventing Clinically Important Gastrointestinal Bleeding During Intensive Care

A Population-Based Study


      Proton pump inhibitors (PPIs) and histamine type 2 receptor blockers (H2Bs) are used for stress ulcer prophylaxis. Although the PPIs have greater potency for acid suppression, their relative effectiveness for preventing clinically important GI bleeding (CIGIB) has not been established. The goal of this study was to determine whether prophylactic PPIs were associated with lower risk of CIGIB than H2Bs among critically ill adults.


      This retrospective cohort study included adults with critical illness from January 1, 2008, to June 30, 2012, who had at least one stress ulcer risk factor and received a PPI or H2B for ≥ 3 days. Cox proportional hazards regression propensity score matching and instrumental variable analyses were used to control for selection bias and confounding by unmeasured factors. The Acute Physiology and Chronic Health Evaluation Score version IV score was used to adjust for differences of acuity. The main outcome and exposure was CIGIB.


      Among 70,093 patients at risk, 49,576 (70.7%) received prophylaxis for at least 3 days, and 424 patients (0.6%) met the definition for experiencing CIGIB. The hazard for CIGIB was two times greater for PPI users compared with H2B users (adjusted hazard ratio, 1.82 [95% CI, 1.19-2.78]; hazard ratio, 2.37 [95% CI, 1.61-3.5]). Sensitivity analyses failed to detect any plausible scenario in which PPIs were superior to H2Bs for the prevention of CIGIB.


      H2Bs were robustly and consistently associated with significantly lower CIGIB risk compared with PPIs in this population.

      Key Words


      APACHE-IV ( Acute Physiology and Chronic Health Evaluation version IV), CIGIB ( clinically important GI bleeding), H2B ( histamine type 2 receptor blocker), HR ( hazard ratio), ICD-9 ( International Classification of Diseases, Ninth Revision), LOS ( length of stay), PPI ( proton pump inhibitor), PSM ( propensity score matching)
      To read this article in full you will need to make a payment
      Subscribe to CHEST
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis. ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 14, 1998.
        Am J Health Syst Pharm. 1999; 56: 347-379
        • Pongprasobchai S.
        • Kridkratoke S.
        • Nopmaneejumruslers C.
        Proton pump inhibitors for the prevention of stress-related mucosal disease in critically-ill patients: a meta-analysis.
        J Med Assoc Thai. 2009; 92: 632-637
        • Barkun A.N.
        • Bardou M.
        • Pham C.Q.
        • Martel M.
        Proton pump inhibitors vs. histamine 2 receptor antagonists for stress-related mucosal bleeding prophylaxis in critically ill patients: a meta-analysis.
        Am J Gastroenterol. 2012; 107: 507-520
        • Zhou J.F.
        • Wan X.Y.
        • Huang W.
        • Han L.L.
        Bleeding and pneumonia in intensive care unit patients given proton pump inhibitor or histamine-2 receptor antagonist for prevention of stress ulcer: a meta analysis.
        Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2010; 22 ([article in Chinese]): 221-225
        • Alhazzani W.
        • Alenezi F.
        • Jaeschke R.Z.
        • Moayyedi P.
        • Cook D.J.
        Proton pump inhibitors versus histamine 2 receptor antagonists for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis.
        Crit Care Med. 2013; 41: 693-705
        • Lin P.C.
        • Chang C.H.
        • Hsu P.I.
        • Tseng P.L.
        • Huang Y.B.
        The efficacy and safety of proton pump inhibitors vs histamine-2 receptor antagonists for stress ulcer bleeding prophylaxis among critical care patients: a meta-analysis.
        Crit Care Med. 2010; 38: 1197-1205
        • MacLaren R.
        • Reynolds P.M.
        • Allen R.R.
        Histamine-2 receptor antagonists vs proton pump inhibitors on gastrointestinal tract hemorrhage and infectious complications in the intensive care unit.
        JAMA Intern Med. 2014; 174: 564-574
        • Cook D.J.
        • Reeve B.K.
        • Scholes L.C.
        Histamine-2-receptor antagonists and antacids in the critically ill population: stress ulceration versus nosocomial pneumonia.
        Infect Control Hosp Epidemiol. 1994; 15: 437-442
        • Cook D.J.
        • Fuller H.D.
        • Guyatt G.H.
        • et al.
        Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials Group.
        N Engl J Med. 1994; 330: 377-381
        • Hammond D.A.
        • Kathe N.
        • Shah A.
        • Martin B.C.
        Cost-effectiveness of histamine2 receptor antagonists versus proton pump inhibitors for stress ulcer prophylaxis in critically ill patients.
        Pharmacotherapy. 2017; 37: 43-53
        • Lilly C.M.
        • Swami S.
        • Liu X.
        • Riker R.R.
        • Badawi O.
        Five-year trends of critical care practice and outcomes.
        Chest. 2017; 152: 723-735
        • Lilly C.M.
        • Zuckerman I.H.
        • Badawi O.
        • Riker R.R.
        Benchmark data from more than 240,000 adults that reflect the current practice of critical care in the United States.
        Chest. 2011; 140: 1232-1242
        • McShea M.
        • Holl R.
        • Badawi O.
        • Riker R.R.
        • Silfen E.
        The eICU research institute—a collaboration between industry, health-care providers, and academia.
        IEEE Eng Med Biol Mag. 2010; 29: 18-25
      2. Cerner All Together, Welcome to APACHE Foundation. 2015. Accessed September 22, 2015.

        • Austin P.C.
        An introduction to propensity score methods for reducing the effects of confounding in observational studies.
        Multivariate Behav Res. 2011; 46: 399-424
        • Terza J.V.
        • Basu A.
        • Rathouz P.J.
        Two-stage residual inclusion estimation: addressing endogeneity in health econometric modeling.
        J Health Econ. 2008; 27: 531-543
        • Wooldridge J.
        Instrumental variables estimation and two stage least squares.
        in: Introductory Economerics: A Modern Approach. South-Western Cengage Learning, Mason, OH2009: 506
        • Binnetoglu E.
        • Akbal E.
        • Sen H.
        • et al.
        Pantoprazole-induced thrombocytopenia in patients with upper gastrointestinal bleeding.
        Platelets. 2015; 26: 10-12
        • Korkmaz U.
        • Alcelik A.
        • Eroglu M.
        • Korkmaz A.N.
        • Aktas G.
        Pantoprazole-induced thrombocytopenia in a patient with upper gastrointestinal bleeding.
        Blood Coagul Fibrinolysis. 2013; 24: 352-353
        • Miller J.L.
        • Gormley A.K.
        • Johnson P.N.
        Pantoprazole-induced thrombocytopenia.
        Indian J Pediatr. 2009; 76: 1278-1279
        • Watson T.D.
        • Stark J.E.
        • Vesta K.S.
        Pantoprazole-induced thrombocytopenia.
        Ann Pharmacother. 2006; 40: 758-761
        • Zlabek J.A.
        • Anderson C.G.
        Lansoprazole-induced thrombocytopenia.
        Ann Pharmacother. 2002; 36: 809-811
        • Lin D.Y.
        • Psaty B.M.
        • Kronmal R.A.
        Assessing the sensitivity of regression results to unmeasured confounders in observational studies.
        Biometrics. 1998; 54: 948-963
        • Hurt R.T.
        • Frazier T.H.
        • McClave S.A.
        • et al.
        Stress prophylaxis in intensive care unit patients and the role of enteral nutrition.
        JPEN J Parenter Enteral Nutr. 2012; 36: 721-731
        • Sesler J.M.
        Stress-related mucosal disease in the intensive care unit: an update on prophylaxis.
        AACN Adv Crit Care. 2007; 18: 119-126
        • Ali T.
        • Harty R.F.
        Stress-induced ulcer bleeding in critically ill patients.
        Gastroenterol Clin North Am. 2009; 38: 245-265
        • Lin J.H.
        Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Relationship between intrinsic potency and effective plasma concentrations.
        Clin Pharmacokinet. 1991; 20: 218-236
        • Shin J.M.
        • Kim N.
        Pharmacokinetics and pharmacodynamics of the proton pump inhibitors.
        J Neurogastroenterol Motility. 2013; 19: 25-35